Volition signs first ever nu.q® vet cancer test automation agreement with fujifilm vet systems

Henderson, nev. , march 13, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announced the expansion of its nu.q® vet cancer test supply agreement (the "agreement") with fujifilm vet systems co. ltd ("fujifilm vet systems") in japan, to include volition's chemiluminescent immunoassay (chlia) version of the test via the immunodiagnostic systems (ids) i10® automated analyzer platform, for a new five year initial term.
VNRX Ratings Summary
VNRX Quant Ranking